Drug discount agreements according to §130a SGB V via open-house
Original notice title
Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren
Opportunity Score
Why this score?
Opportunity
62 / 100
Complexity
58 / 100
Risk factors
Electronic submission is explicitly not allowed; the buyer says electronic filing would only be accessible after the pr...
Participation is restricted to pharmaceutical undertakings or consortia of pharmaceutical undertakings under § 4(18) AM...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- IKK classic
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- May 05, 2028
Overview
Moderate opportunityKey Facts
- Supplies contract
- 3 lots
- Duration until Jun 2028
- Non-exclusive pharmaceutical discount agreements under § 130a(8) SGB V for multiple active substances and combinations.
- Open-house accession model with equal, non-negotiable conditions for all suitable pharmaceutical companies.
Show full summary
Open-house pharmaceutical discount agreement procedure by IKK classic for 32 named active substances/combination products in Germany. The notice states non-exclusive, non-negotiable terms, with continuous accession possible until 05.05.2028. Submission is not electronic; signed documents and supporting evidence must be sent by post or email to the buyer. Procurement documents were available via DTVP and some extracted notice text was analyzed, but the full procurement documents were not fully available in the input.
Risks
Electronic submission is explicitly not allowed; the buyer says electronic filing would only be accessible after the pr...
Participation is restricted to pharmaceutical undertakings or consortia of pharmaceutical undertakings under § 4(18) AM...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical undertakings or groups of pharmaceutical undertakings within the meaning of § 4(18) AMG are eligible.
Administrative
- Signed contract and all required supporting documents, self-declarations and evidence must be submitted.
- Submission is not allowed electronically; documents must be sent by post or email to [email protected].
Buyer
Lots (32)
LOT-0001
Adalimumab (excluding 80 mg)
Open-house supply agreement for Adalimumab, excluding 80 mg, ATC L04AB04. The lot is for a pharmaceutical product and performance is in Germany (DED21).
Location
Duration
Category
Deadline
Award details
Adalimumab
ohne 80 mg
ATC-Code: L04AB04
Value note
Show original TED data
Original lot title
Adalimumab; ohne 80 mg; ATC-Code: L04AB04
Original TED description
Adalimumab; ohne 80 mg; ATC-Code: L04AB04
LOT-0002
Adapalene and benzoyl peroxide
Open-house supply agreement for Adapalene 3 mg/g and Benzoyl peroxide 25 mg/g, ATC D10AD23 / D10AD53. Performance is in Germany (DED21).
Location
Duration
Category
Deadline
Award details
Adapalen 3 mg/g und Benzoylperoxid 25 mg/g
ATC-Code: D10AD23 (ADV), D10AD53 (WHO)
Value note
Show original TED data
Original lot title
Adapalen 3 mg/g und Benzoylperoxid 25 mg/g ; ATC-Code: D10AD23 (ADV), D10AD53 (WHO)
Original TED description
Adapalen 3 mg/g und Benzoylperoxid 25 mg/g ; ATC-Code: D10AD23 (ADV), D10AD53 (WHO)
LOT-0003
Aflibercept
Open-house supply agreement for Aflibercept 40 mg/ml, ATC S01LA05. Performance is in Germany (DED21).
Location
Duration
Category
Deadline
Award details
Aflibercept
40 mg/ml
ATC-Code: S01LA05
Value note
Show original TED data
Original lot title
Aflibercept; 40 mg/ml; ATC-Code: S01LA05
Original TED description
Aflibercept; 40 mg/ml; ATC-Code: S01LA05
LOT-0004
Alglucosidase alfa; ATC-Code: A16AB07
Alglucosidase alfa; ATC-Code: A16AB07
Location
Duration
Category
Award details
Alglucosidase alfa
ATC-Code: A16AB07
LOT-0005
Bimatoprost; Wirkstärke 0,1 mg/ml; ATC-Code: S01EE03
Bimatoprost; Wirkstärke 0,1 mg/ml; ATC-Code: S01EE03
Location
Duration
Category
Award details
Bimatoprost
Wirkstärke 0,1 mg/ml
ATC-Code: S01EE03
LOT-0006
Biperiden; ATC-Code: N04AA02
Biperiden; ATC-Code: N04AA02
Location
Duration
Category
Award details
Biperiden
ATC-Code: N04AA02
LOT-0007
Brolucizumab; ATC-Code: S01LA06
Brolucizumab; ATC-Code: S01LA06
Location
Duration
Category
Award details
Brolucizumab
ATC-Code: S01LA06
LOT-0008
Budesonid; Magensaftresistente Hartkapseln; ATC-Code: A07EA06
Budesonid; Magensaftresistente Hartkapseln; ATC-Code: A07EA06
Location
Duration
Category
Award details
Budesonid
Magensaftresistente Hartkapseln
ATC-Code: A07EA06
LOT-0009
Dabrafenib; ATC-Code: L01EC02
Dabrafenib; ATC-Code: L01EC02
Location
Duration
Category
Award details
Dabrafenib
ATC-Code: L01EC02
LOT-0010
Dalteparin; ATC-Code: B01AB04
Dalteparin; ATC-Code: B01AB04
Location
Duration
Category
Award details
Dalteparin
ATC-Code: B01AB04
LOT-0011
Diazepam; ATC-Code: N05BA01
Diazepam; ATC-Code: N05BA01
Location
Duration
Category
Award details
Diazepam
ATC-Code: N05BA01
LOT-0012
Dimethylfumarat - zur Behandlung der schubförmig remittierenden MS; Wirkstärke 120 mg, Packungsgröße 28 HKM und 56 HKM (N2); Wirkstärke 240 mg, Packungsgröße 196 HKM (N3); ATC-Code: L04AX07
Dimethylfumarat - zur Behandlung der schubförmig remittierenden MS; Wirkstärke 120 mg, Packungsgröße 28 HKM und 56 HKM (N2); Wirkstärke 240 mg, Packungsgröße 196 HKM (N3); ATC-Code: L04AX07
Location
Duration
Category
Award details
Dimethylfumarat - zur Behandlung der schubförmig remittierenden MS
Wirkstärke 120 mg, Packungsgröße 28 HKM und 56 HKM (N2)
Wirkstärke 240 mg, Packungsgröße 196 HKM (N3)
ATC-Code: L04AX07
LOT-0013
Eisen, parenterale Darreichungsformen: Eisen(III)-hydroxid-Saccharose-Komplex; Eisen(III)-hydroxid-Dextran-Komplex; Eisen(III)-Natrium-D-gluconat-Komplex; Eisenderisomaltose; ATC-Code: B03AC02, B03AC06, B03AC07, B03AC08 (ADV); B03AC (WHO)
Eisen, parenterale Darreichungsformen: Eisen(III)-hydroxid-Saccharose-Komplex; Eisen(III)-hydroxid-Dextran-Komplex; Eisen(III)-Natrium-D-gluconat-Komplex; Eisenderisomaltose; ATC-Code: B03AC02, B03AC06, B03AC07, B03AC08 (ADV); B03AC (WHO)
Location
Duration
Category
Award details
Eisen, parenterale Darreichungsformen: Eisen(III)-hydroxid-Saccharose-Komplex
Eisen(III)-hydroxid-Dextran-Komplex
Eisen(III)-Natrium-D-gluconat-Komplex
Eisenderisomaltose
ATC-Code: B03AC02, B03AC06, B03AC07, B03AC08 (ADV)
B03AC (WHO)
LOT-0014
Epoetin alfa und Epoetin zeta; ATC-Code: B03XA01
Epoetin alfa und Epoetin zeta; ATC-Code: B03XA01
Location
Duration
Category
Award details
Epoetin alfa und Epoetin zeta
ATC-Code: B03XA01
LOT-0015
Etanercept; ATC-Code: L04AB01
Etanercept; ATC-Code: L04AB01
Location
Duration
Category
Award details
Etanercept
ATC-Code: L04AB01
LOT-0016
Filgrastim; ATC-Code: L03AA02
Filgrastim; ATC-Code: L03AA02
Location
Duration
Category
Award details
Filgrastim
ATC-Code: L03AA02
LOT-0017
Glibenclamid; ATC-Code: A10BB01
Glibenclamid; ATC-Code: A10BB01
Location
Duration
Category
Award details
Glibenclamid
ATC-Code: A10BB01
LOT-0018
Lercanidipin; ATC-Code: C08CA13
Lercanidipin; ATC-Code: C08CA13
Location
Duration
Category
Award details
Lercanidipin
ATC-Code: C08CA13
LOT-0019
Mepolizumab; ATC-Code: R03DX09
Mepolizumab; ATC-Code: R03DX09
Location
Duration
Category
Award details
Mepolizumab
ATC-Code: R03DX09
LOT-0020
Pegfilgrastim; ATC-Code: L03AA13
Pegfilgrastim; ATC-Code: L03AA13
Location
Duration
Category
Award details
Pegfilgrastim
ATC-Code: L03AA13
LOT-0021
Propranolol; Lösung zum Einnehmen; ATC-Code: C07AA05
Propranolol; Lösung zum Einnehmen; ATC-Code: C07AA05
Location
Duration
Category
Award details
Propranolol
Lösung zum Einnehmen
ATC-Code: C07AA05
LOT-0022
Risperidon; Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension; 75 mg und 100 mg; ATC-Code: N05AX08
Risperidon; Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension; 75 mg und 100 mg; ATC-Code: N05AX08
Location
Duration
Category
Award details
Risperidon
Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension
75 mg und 100 mg
ATC-Code: N05AX08
LOT-0023
Stiripentol; ATC-Code: N03AX17
Stiripentol; ATC-Code: N03AX17
Location
Duration
Category
Award details
Stiripentol
ATC-Code: N03AX17
LOT-0024
Tafluprost; ATC-Code: S01EE05
Tafluprost; ATC-Code: S01EE05
Location
Duration
Category
Award details
Tafluprost
ATC-Code: S01EE05
LOT-0025
Tafluprost und Timolol; ATC-Code: S01ED70 (ADV), S01ED51 (WHO)
Tafluprost und Timolol; ATC-Code: S01ED70 (ADV), S01ED51 (WHO)
Location
Duration
Category
Award details
Tafluprost und Timolol
ATC-Code: S01ED70 (ADV), S01ED51 (WHO)
LOT-0026
Teriparatid; ATC-Code: H05AA02
Teriparatid; ATC-Code: H05AA02
Location
Duration
Category
Award details
Teriparatid
ATC-Code: H05AA02
LOT-0027
Tofacitinib; ATC-Code: L04AF01
Tofacitinib; ATC-Code: L04AF01
Location
Duration
Category
Award details
Tofacitinib
ATC-Code: L04AF01
LOT-0028
Trientin; Filmtabletten 150 mg; Hartkapseln 100 mg; ATC-Code: A16AX12
Trientin; Filmtabletten 150 mg; Hartkapseln 100 mg; ATC-Code: A16AX12
Location
Duration
Category
Award details
Trientin
Filmtabletten 150 mg
Hartkapseln 100 mg
ATC-Code: A16AX12
LOT-0029
Vitamine, Kombinationen; Cernevit(R), Frekavit(R), Natrovit(R), Soluvit(R), Viant(R), Vitalipid(R); ATC-Code: B05XC30 (ADV), B05XC (WHO)
Vitamine, Kombinationen; Cernevit(R), Frekavit(R), Natrovit(R), Soluvit(R), Viant(R), Vitalipid(R); ATC-Code: B05XC30 (ADV), B05XC (WHO)
Location
Duration
Category
Award details
Vitamine, Kombinationen
Cernevit(R), Frekavit(R), Natrovit(R), Soluvit(R), Viant(R), Vitalipid(R)
ATC-Code: B05XC30 (ADV), B05XC (WHO)
LOT-0030
Tocilizumab; ATC-Code: L04AC07
Tocilizumab; ATC-Code: L04AC07
Location
Duration
Category
Award details
Tocilizumab
ATC-Code: L04AC07
LOT-0031
Ivermectin; Creme; ATC-Code: D11AX22
Ivermectin; Creme; ATC-Code: D11AX22
Location
Duration
Category
Award details
Ivermectin
Creme
ATC-Code: D11AX22
LOT-0032
Propranolol; Filmtabletten, Tabletten; ATC-Code: C07AA05
Propranolol; Filmtabletten, Tabletten; ATC-Code: C07AA05
Location
Duration
Category
Award details
Propranolol
Filmtabletten, Tabletten
ATC-Code: C07AA05
Procurement Details
- Publication date
- 21 Jun 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 426545-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
62 / 100
Complexity
58 / 100
Risk factors
Electronic submission is explicitly not allowed; the buyer says electronic filing would only be accessible after the pr...
Participation is restricted to pharmaceutical undertakings or consortia of pharmaceutical undertakings under § 4(18) AM...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications